Medicare GLP-1 Bridge for 2027: A Practical Agent Guide

Updated October 7, 2026. Prepared for the 2027 coverage year using current CMS guidance.

The Medicare GLP-1 Bridge is operating now and is scheduled to continue through December 31, 2027. Eligible Medicare beneficiaries can receive certain GLP-1 medications for weight management for a $50 copay per monthly supply through this temporary CMS demonstration. The program began July 1, 2026. CMS

For agents, the useful question is more specific than whether Medicare covers a weight-loss drug: Which coverage route applies to this client, and what needs to happen next?

This guide explains the current eligibility rules, how the Bridge differs from ordinary Part D coverage, and how to help a client move from a prescription to a coverage decision. It also identifies a 2027 eligibility issue that CMS has not yet resolved in its published guidance.

What continues into 2027

CMS extended the Bridge through the end of 2027 after delaying the Medicare Part D portion of the BALANCE Model. BALANCE is not launching in Medicare Part D in 2027. The extension does not establish a guaranteed replacement program for January 2028. cms.gov

Keep three dates separate in the client record: the program’s scheduled end date, the client’s prior authorization approval, and the effective date of any plan change. A drug approval and a plan enrollment answer different questions.

The Bridge operates outside the Part D benefit’s coverage and payment system. Part D insurers do not have to opt in for otherwise eligible members to access it. It is not a benefit that a particular Medicare Advantage carrier adds to its plan. cms.gov

Start with the correct coverage route

Basic Part D generally excludes drugs when used for weight loss. A GLP-1 can be eligible for ordinary Part D coverage when prescribed for a different, Part D-coverable indication. The prescribing purpose matters; the drug’s brand name alone does not determine the route.

The underlying exclusion appears in Social Security Act section 1860D-2(e)(2)(A), incorporating section 1927(d)(2)(A). ssa.gov

These diagnoses require particular care

Current CMS guidance excludes beneficiaries with the following diagnoses from the Bridge:

• Type 2 diabetes
• Moderate-to-severe obstructive sleep apnea
• Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, stages F2–F3

These are conditions for which GLP-1 treatment can be coverable under Part D. The exclusion applies even when the requested product is missing from the client’s formulary or the plan denies the request. CMS

Do not broaden those criteria to every case of sleep apnea or every liver condition. The prescriber must determine whether the specified diagnosis applies. Choosing a different GLP-1 or describing it as a weight-loss prescription does not bypass a beneficiary-level exclusion. CMS

Cardiovascular history needs a more specific question

A history of heart attack, stroke or symptomatic peripheral artery disease can help satisfy one of the Bridge’s BMI pathways. But a GLP-1 prescribed to reduce major adverse cardiovascular events belongs in Part D when that use is coverable there.

Established cardiovascular disease alone does not automatically rule out the Bridge; the prescribing purpose and other eligibility facts matter. cms.gov

Example: A client reports a previous heart attack and asks about Wegovy. Ask the prescribing office to confirm whether the prescription is for cardiovascular risk reduction, weight management, or both. A prescription that includes a Part D-coverable purpose should be handled through Part D. Do not select the indication based on which route has the lower copay. CMS

A Part D denial is not required before starting a potential Bridge prescription. The required first pharmacy claim is explained below; it is a claim to the Bridge. CMS

Check coverage and clinical eligibility

Verify the actual Medicare coverage arrangement

Under current published criteria, eligible arrangements include a standalone Part D plan and Medicare Advantage coordinated care plans with drug coverage, such as HMOs and PPOs.

Eligible Part D members can include people in Special Needs Plans, employer or union group waiver plans, and the Limited Income Newly Eligible Transition (LI NET) program. Medicare and Medicaid eligibility does not itself prevent access. CMS

Other arrangements require closer review. CMS identifies private fee-for-service plans, certain cost and prepayment plans, PACE, fallback plans and religious fraternal benefit plans as excluded unless a permitted standalone PDP arrangement applies. Do not infer that a PACE participant can simply add a PDP. Verify the specific coverage arrangement with Medicare. CMS

The detailed CMS plan-type guidance still contains references to calendar year 2026. For a 2027 recommendation, check for updated instructions and confirm both current and proposed coverage. CMS

Use the BMI at the start of GLP-1 therapy

The patient must be at least 18, and treatment must be for weight reduction and maintenance with the required lifestyle measures. The current PA form addresses structured nutrition and physical activity, with an exception when physical activity is not clinically appropriate. cms.gov

For this program, uncontrolled hypertension means systolic pressure above 140 mm Hg or diastolic pressure above 90 mm Hg despite concurrent treatment with two antihypertensive medications. The prescriber applies the diagnostic criteria, including the American Diabetes Association definition of prediabetes. cms.gov

The relevant BMI can predate Medicare enrollment or the Bridge’s launch. Weight loss after treatment starts does not mean the office should substitute today’s lower BMI for the initial measurement. CMS

Example: A cash-paying patient began treatment at a BMI of 37 and now has a BMI of 31. The useful next step is to ask the office to review the documented starting BMI and the remaining Bridge criteria. Today’s measurement alone does not settle eligibility.

Review prior Part D use before predicting 2027 eligibility

For 2026, a beneficiary who received a GLP-1 through Part D during calendar year 2026 is ineligible for the Bridge in 2026. This includes applicable supplemental Part D coverage for weight management, such as through an employer plan. The review is not limited to the exact drug the client now wants. CMS

As of October 7, 2026, CMS’s published FAQ says it has not determined the prior-use lookback period it will apply in 2027. Do not promise a January 1 reset, or tell a client that any past Part D GLP-1 use creates a lifetime exclusion. CMS

Record the drug, fill date and payer. A pharmacy receipt, plan EOB or prescribing-office record is more useful than “I tried a shot last year.” Distinguish Part D-paid use from cash purchases and Bridge fills.

If the answer affects a 2027 recommendation, leave a specific follow-up item to recheck the CMS Part D-plan FAQ and confirm eligibility.

Confirm the exact product and formulation

The current Bridge list includes the following products for eligible weight-management use:

Zepbound single-dose pens and single-dose vials are excluded from the current Bridge list. Ozempic, Rybelsus and Mounjaro are not on that list. An approval for one product does not authorize an interchangeable choice among all GLP-1 drugs. CMS

Ask for the exact name and formulation rather than recording “GLP-1” in the client file. If the pharmacy reports that the product is ineligible, have it compare the dispensed product’s National Drug Code with CMS’s current list. CMS can update the list during the demonstration. CMS

Explain the cost before the first fill

An eligible Bridge fill costs $50 for a 28-day or 30-day supply. The program does not support 60-day or 90-day supplies or partial fills. CMS

These distinctions follow CMS’s Bridge billing guidance, sponsor guidance and Medicare’s beneficiary materials. cms.gov

For 2027, the standard Part D deductible is $700 and the annual Part D out-of-pocket threshold is $2,400. Individual plans can have lower deductibles. Those figures concern the Part D benefit; Bridge spending sits outside it. cms.gov

Budget example: Twelve eligible monthly fills at $50 total $600. That is an illustration, not an annual maximum; use the actual dispensing schedule, particularly with 28-day supplies. A client who reaches the Part D threshold through other covered medicines still needs to budget for Bridge fills.

Zepbound KwikPen needles are purchased separately; CMS says they should not be billed to the Bridge or the patient’s Part D plan. Coupons and routine copay-subsidy programs cannot be applied to the Bridge copay. Keep pharmacy receipts: Bridge spending does not appear on the Part D EOB or Medicare Summary Notice. CMS

Follow the pharmacy and prescriber sequence

A useful agent follow-up tracks the handoff, the person responsible and the unresolved item.

1. Confirm the prescription and destination pharmacy. Record the product and formulation, and obtain clarification of the coverage route from the prescribing office.

2. The prescriber sends the prescription to the pharmacy. CMS recommends an appropriate E66 diagnosis code and a note such as “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” to help routing. These are recommended aids, not universal prerequisites. cms.gov

3. The pharmacy submits the initial Bridge claim. It uses the client’s current Medicare information. A response requesting prior authorization is an expected processing step. cms.gov

4. The prescribing office submits the clinical PA. The first Bridge claim must already exist. Submitting the PA first can produce a patient-not-found response. Prescribing clinicians complete the clinical request; agents can help the client identify and contact the office responsible. cms.gov

5. Track the decision and the actual fill. Record when the request was sent, whether more information is needed, and whether the pharmacy successfully dispensed the approved product.

CMS describes two separate timing intervals: the pharmacy’s PA request generally reaches the prescribing office within 24–72 hours, and the submitted PA decision is communicated within 72 hours. These are not a promise that every step from the initial appointment through dispensing will finish in three days. cms.gov

If the office has not received the pharmacy’s PA request after 72 hours, it can download and submit the official fax form after confirming that the initial Bridge claim has been submitted. cms.gov

For a stalled case, use a concrete question:

That gives both offices a specific step to check.

Carry the approval into the 2027 review

Medicare.gov says approval remains valid through December 31, 2027, including refills and dose changes, unless the patient changes GLP-1 drugs. A change of drug requires a new PA. Medicare

Continued eligibility still matters. CMS identifies later Part D GLP-1 use and movement into an ineligible plan type as possible reasons an approved patient’s refill can reject. Keep the approval letter, then recheck eligibility when the client’s medication or coverage circumstances change. CMS

Identify the reason a claim or request failed

“It was denied” does not identify the next action. Ask which system issued the response and obtain the actual message.

The CMS pharmacy reject-code tool helps distinguish administrative errors, product exclusions, PA requirements and eligibility problems. Link it in the follow-up record when pharmacy staff need technical detail. cms.gov

For a Bridge clinical PA denial, CMS currently describes no Bridge appeals process, but the prescriber may resubmit with corrected, updated or additional information. That is the program’s stated procedure; it should not be confused with Part D’s separate appeal system. CMS

For a Part D denial, Medicare’s coverage-determination, exception and appeal rights remain available under the applicable rules. A missing formulary listing does not by itself make the client eligible for the Bridge. Medicare

Complete the full 2027 plan review

Bridge access is one part of an annual review. Build the recommendation around the client’s complete coverage needs:

• Verify the exact proposed 2027 plan, effective date and coverage type.
• Review the other prescriptions, formularies, pharmacy access and expected Part D costs.
• For Medicare Advantage, review providers, hospitals, medical cost sharing and relevant prior authorization requirements.
• For a client with Medicaid or a Special Needs Plan, confirm the separate eligibility and coordination issues.
• Record Bridge spending separately from Part D estimates.
• Identify the actual enrollment period before submitting a plan change.

Bridge interest alone does not establish a Special Enrollment Period. Use the client’s actual enrollment circumstances. The companion Medicare Special Enrollment Period guide can support that separate review. Medicare

CMS permits neutral education about the Bridge but directs plan sponsors not to present it as their own benefit or suggest access is tied to a particular plan. Agents should avoid descriptions such as a carrier’s “$50 GLP-1 plan.” cms.gov

Account for negotiated drug prices without confusing the programs

The Medicare Drug Price Negotiation Program’s negotiated prices for the selected Ozempic, Rybelsus and Wegovy drug grouping take effect January 1, 2027. These are negotiated drug prices, not a universal member copay. Review the client’s actual 2027 plan cost sharing and utilization management for a Part D-coverable prescription. cms.gov

Price negotiation does not itself remove the basic Part D exclusion for weight-loss use. It also does not change the Bridge’s separate $50 copay. A price headline cannot establish the client’s coverage route. ssa.gov

For the broader benefit changes, use the 2027 Medicare Part D agent guide. For a Medicare Advantage comparison, pair the review with the 2027 county-level Medicare Advantage guide.

A practical way to explain it to a client

Printable agent checklist

Medicare GLP-1 Bridge review
Current guidance checked October 7, 2026

Client or internal reference: ____________________
Review date: ____________________

Current plan: ____________________
Proposed 2027 plan: ____________________

Drug and formulation: ____________________
Prescribing office: ____________________

• Exact product, formulation and pharmacy recorded.
• Prescribing office identified to confirm the treatment purpose and coverage route.
• Current and proposed Part D coverage arrangements checked for Bridge eligibility.
• Prior GLP-1 fills reviewed by drug, date and payer; any unresolved 2027 lookback question flagged.
• Office asked to review baseline BMI, clinical criteria and applicable exclusions.
• Pharmacy has the client’s current Medicare information.
• Initial Bridge claim submitted; actual response and next action recorded.
• PA request received by the office; submission and decision dates recorded.
• First paid fill confirmed, or the unresolved issue assigned for follow-up.
• Copay, supply limits, separate Part D accounting and any needle expense explained.
• Existing approval and refill needs reviewed before any drug or plan change.
• Complete 2027 drug and medical coverage review finished; enrollment period verified if changing plans.

Pending issue and responsible person:
__________________________________________________

Next follow-up date and expected action:
__________________________________________________

Use with the current CMS instructions and the client’s actual records. A checked worksheet supports follow-up; it does not establish clinical or program eligibility.

Questions clients are likely to ask

Is Ozempic included in the Bridge?

Ozempic is not on the current Bridge list. It can be a Part D coverage question when prescribed for a coverable use. Ask the prescribing office about the appropriate treatment and coverage route; do not promise access by substituting a brand name. Medicare

Do I need a Humana insurance plan?

No. Humana’s central processing role does not require enrollment in a Humana insurance plan. Check the client’s eligible Part D coverage arrangement and the Bridge requirements. CMS

Can someone with Medicare and Medicaid qualify?

Potentially, yes, if the person meets the program’s coverage and clinical requirements. Extra Help does not reduce the Bridge’s $50 copay. Verify the individual facts and budget rather than assuming Medicaid status settles the question. CMS

Will coverage automatically continue after 2027?

The current demonstration runs through December 31, 2027. CMS has not established a guaranteed January 2028 successor in the guidance reviewed for this article. Recheck the program’s status before advising clients about coverage beyond that date. cms.gov

Where to get help

Contact information comes from Medicare.gov, CMS provider guidance and the pharmacy payer sheet. Medicare

The current prescriber PA form supports electronic submission through CoverMyMeds or fax to 1-800-530-2404. The current pharmacy payer sheet identifies BIN 028918 and PCN MEDDGLP1BR. Share the official form or payer sheet so the office or pharmacy can use the current instructions. cms.gov

The most useful agent record ends with a resolved coverage route, an accurate cost discussion and a named next action. Informed+Choice’s Annual Review workflow can support an organized review of medications, coverage questions and follow-up tasks.

Official sources and working resources

Sources reviewed October 7, 2026. Check current CMS instructions when resolving an individual case.

1. CMS program launch
   https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications

2. Bridge extension and Medicare Part D BALANCE status for 2027
   https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf

3. CMS expectations and FAQs for Part D sponsors
   https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf

4. Social Security Act section 1860D-2
   https://www.ssa.gov/OP_Home/ssact/title18/1860D-02.htm

5. Social Security Act section 1927
   https://www.ssa.gov/OP_Home/ssact/title19/1927.htm

6. CMS information for providers
   https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers

7. Current prior authorization form
   https://www.cms.gov/glp-1-bridge.pdf

8. CMS prescriber fact sheet
   https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf

9. Medicare.gov weight-loss drug coverage and Bridge information
   https://www.medicare.gov/coverage/weight-loss-drugs

10. CMS information for Part D plans, including the 2027 lookback question
    https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans

11. CMS information for pharmacies
    https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies

12. Medicare beneficiary handout
    https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf

13. Final 2027 Part D benefit parameters, Attachment V
    https://www.cms.gov/files/document/2027-announcement.pdf

14. Pharmacy reject-code troubleshooting reference
    https://www.cms.gov/files/document/medicare-glp-1-bridge-pharmacy-reject-code-reference-tool.pdf

15. Medicare Part D appeals
    https://www.medicare.gov/providers-services/claims-appeals-complaints/appeals/drug-plans

16. Negotiated prices taking effect in 2027
    https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf

17. Current pharmacy payer sheet
    https://www.cms.gov/files/document/glp-1-bridge-payer-sheet.pdf

18. Medicare Special Enrollment Periods
    https://www.medicare.gov/basics/get-started-with-medicare/get-more-coverage/joining-a-plan/special-enrollment-periods